Skip to main content
Top
Published in: Diabetes Therapy 2/2023

Open Access 21-01-2023 | Insulins | Review

Epidemiological, Social and Economic Burden of Severe Hypoglycaemia in Patients with Diabetes Mellitus in Portugal: A Structured Literature Review

Authors: Ana Rita Soares, Marisa Coelho, Marsha Tracey, Davide Carvalho, José Silva-Nunes

Published in: Diabetes Therapy | Issue 2/2023

Login to get access

Abstract

Introduction

The aim of this review was to identify and review studies reporting on the epidemiological, social and economic impact associated with severe hypoglycaemia (SH) in people with diabetes mellitus (DM) in Portugal.

Methods

A structured literature search was carried out in PubMed and Embase using a predefined selection criterion. Studies published in either Portuguese or English, between January 2010 and February 2021 were deemed eligible for inclusion.

Results

Twelve studies including adults (aged ≥ 18 years) with type 1 and/or type 2 diabetes mellitus (T1DM/T2DM) were eligible for inclusion. Epidemiological estimates varied according to the setting and type of data source used. The proportion of patients who experienced ≥ 1 SH episode (SHE) in the previous 6–12 months varied from 3.1% in adults with T2DM to 36.8% in adults with T1DM. In adults with T2DM the prevalence in a community-based study was highest in the insulin and secretagogue combination treated group (9.1%), while in an emergency department setting prevalence was highest in the insulin-based therapy group and the oral hypoglycaemic agent without secretagogues group (32.0% and 20.0%, respectively). The prevalence of SH in other studies in patients with DM ranged from 0.1% (emergency department) to 18.1% (hospital ward). Patients treated with secretagogues had the highest rates of hospitalisations. In patients with T1DM, the annual rate of SHE was higher in those with impaired hypoglycaemia awareness than in those with intact awareness. Mean total cost (direct and indirect) per SHE ranged from €1493.00 in patients with T2DM treated in an emergency setting to €2608.51 in patients with T1DM who were hospitalised.

Conclusion

Hypoglycaemic events, especially SHE, have a significant effect on the life of persons living with DM and their caregivers. Studies show that the prevalence of this acute complication of diabetes is not negligible. In addition to the negative impact on the quality of life, the burden of SHE in Portugal translates into a significant impact on the global health expenditure.
Appendix
Available only for authorised users
Literature
2.
go back to reference Nathan DM, et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14):977–86.PubMedCrossRef Nathan DM, et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14):977–86.PubMedCrossRef
3.
go back to reference Holman RR, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359(15):1577–89.PubMedCrossRef Holman RR, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359(15):1577–89.PubMedCrossRef
4.
go back to reference Association AD. 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes—2021. Diabetes Care. 2021;44(1):111–1124.CrossRef Association AD. 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes—2021. Diabetes Care. 2021;44(1):111–1124.CrossRef
5.
go back to reference Raposo JF. Diabetes: factos e Números 2016, 2017 e 2018. Revista Portuguesa de Diabetes. 2020;15(1):19–27. Raposo JF. Diabetes: factos e Números 2016, 2017 e 2018. Revista Portuguesa de Diabetes. 2020;15(1):19–27.
6.
go back to reference IDF. <IDF_Atlas_10th_Edition_2021.pdf>. 2021. IDF. <IDF_Atlas_10th_Edition_2021.pdf>. 2021.
7.
go back to reference Risso T, Furtado C. Rational use of blood glucose test strips for self-monitoring in patients with diabetes mellitus: economic impact in the Portuguese healthcare system. Diabetes Res Clin Pract. 2017;134:161–7.PubMedCrossRef Risso T, Furtado C. Rational use of blood glucose test strips for self-monitoring in patients with diabetes mellitus: economic impact in the Portuguese healthcare system. Diabetes Res Clin Pract. 2017;134:161–7.PubMedCrossRef
8.
go back to reference Tavares AI, Marques I. Multi-layer health insurance coverage, medical services use and health in a Universal National Health System, the case of Portugal. Eur J Health Econ. 2021;22(1):141–53.PubMedCrossRef Tavares AI, Marques I. Multi-layer health insurance coverage, medical services use and health in a Universal National Health System, the case of Portugal. Eur J Health Econ. 2021;22(1):141–53.PubMedCrossRef
9.
go back to reference Williams R, et al. Global and regional estimates and projections of diabetes-related health expenditure: results from the international diabetes federation diabetes atlas. Diabetes Res Clin Pract. 2020;162:108072.PubMedCrossRef Williams R, et al. Global and regional estimates and projections of diabetes-related health expenditure: results from the international diabetes federation diabetes atlas. Diabetes Res Clin Pract. 2020;162:108072.PubMedCrossRef
10.
11.
go back to reference Alao S, et al. Hypoglycemic episodes in hospitalized people with diabetes in Portugal: the HIPOS-WARD study. Clin Diabet Endocrinol. 2021;7(1):2.CrossRef Alao S, et al. Hypoglycemic episodes in hospitalized people with diabetes in Portugal: the HIPOS-WARD study. Clin Diabet Endocrinol. 2021;7(1):2.CrossRef
12.
go back to reference American Diabetes Association Professional Practice. 6. Glycemic targets: standards of medical care in diabetes-2022. Diabetes Care. 2022;45(Suppl 1):S83–96.CrossRef American Diabetes Association Professional Practice. 6. Glycemic targets: standards of medical care in diabetes-2022. Diabetes Care. 2022;45(Suppl 1):S83–96.CrossRef
13.
go back to reference Towler DA, et al. Mechanism of awareness of hypoglycemia. Perception of neurogenic (predominantly cholinergic) rather than neuroglycopenic symptoms. Diabetes. 1993;42(12):1791–8.PubMedCrossRef Towler DA, et al. Mechanism of awareness of hypoglycemia. Perception of neurogenic (predominantly cholinergic) rather than neuroglycopenic symptoms. Diabetes. 1993;42(12):1791–8.PubMedCrossRef
14.
go back to reference Silbert R, et al. Hypoglycemia among patients with type 2 diabetes: epidemiology, risk factors, and prevention strategies. Curr Diab Rep. 2018;18(8):53.PubMedPubMedCentralCrossRef Silbert R, et al. Hypoglycemia among patients with type 2 diabetes: epidemiology, risk factors, and prevention strategies. Curr Diab Rep. 2018;18(8):53.PubMedPubMedCentralCrossRef
15.
go back to reference American Diabetes Association (ADA). 4. Comprehensive medical evaluation and assessment of comorbidities: standards of medical care in diabetes-2021. Diabetes Care. 2021;44(Suppl 1):S40-s52.CrossRef American Diabetes Association (ADA). 4. Comprehensive medical evaluation and assessment of comorbidities: standards of medical care in diabetes-2021. Diabetes Care. 2021;44(Suppl 1):S40-s52.CrossRef
16.
go back to reference Dømgaard M, et al. Individual and societal consequences of hypoglycemia: a cross-sectional survey. Postgrad Med. 2015;127(5):438–45.PubMedCrossRef Dømgaard M, et al. Individual and societal consequences of hypoglycemia: a cross-sectional survey. Postgrad Med. 2015;127(5):438–45.PubMedCrossRef
17.
go back to reference Rossi MC, et al. Impact of severe and symptomatic hypoglycemia on quality of life and fear of hypoglycemia in type 1 and type 2 diabetes. Results of the Hypos-1 observational study. Nutr Metab Cardiovasc Dis. 2019;29(7):736–43.PubMedCrossRef Rossi MC, et al. Impact of severe and symptomatic hypoglycemia on quality of life and fear of hypoglycemia in type 1 and type 2 diabetes. Results of the Hypos-1 observational study. Nutr Metab Cardiovasc Dis. 2019;29(7):736–43.PubMedCrossRef
18.
go back to reference Ampudia-Blasco FJ, et al. Conversations and reactions around severe hypoglycaemia (CRASH): Spanish results of a global survey of people with type 1 diabetes or insulin-treated type 2 diabetes and caregivers. Endocrinol Diabetes Nutr. 2021;2:2. Ampudia-Blasco FJ, et al. Conversations and reactions around severe hypoglycaemia (CRASH): Spanish results of a global survey of people with type 1 diabetes or insulin-treated type 2 diabetes and caregivers. Endocrinol Diabetes Nutr. 2021;2:2.
19.
go back to reference Hoskins N, Tikkanen CK, Pedersen-Bjergaard U. The economic impact of insulin-related hypoglycemia in Denmark: an analysis using the local impact of hypoglycemia tool. J Med Econ. 2017;20(4):363–70.PubMedCrossRef Hoskins N, Tikkanen CK, Pedersen-Bjergaard U. The economic impact of insulin-related hypoglycemia in Denmark: an analysis using the local impact of hypoglycemia tool. J Med Econ. 2017;20(4):363–70.PubMedCrossRef
20.
go back to reference Parekh W, et al. The economic burden of insulin-related hypoglycemia in adults with diabetes: an analysis from the perspective of the Italian healthcare system. Diabetes Ther. 2018;9(3):1037–47.PubMedPubMedCentralCrossRef Parekh W, et al. The economic burden of insulin-related hypoglycemia in adults with diabetes: an analysis from the perspective of the Italian healthcare system. Diabetes Ther. 2018;9(3):1037–47.PubMedPubMedCentralCrossRef
21.
go back to reference International Diabetes Federation (IDF). IDF Diabetes Atlas 2019, 9th edition. 2019. International Diabetes Federation (IDF). IDF Diabetes Atlas 2019, 9th edition. 2019.
22.
go back to reference Conceicao J, et al. Severe hypoglycaemia among patients with type 2 diabetes requiring emergency hospital admission: the hypoglycaemia in Portugal observational study-emergency room (HIPOS-ER). Diabetes Obes Metab. 2018;20(1):50–9.PubMedCrossRef Conceicao J, et al. Severe hypoglycaemia among patients with type 2 diabetes requiring emergency hospital admission: the hypoglycaemia in Portugal observational study-emergency room (HIPOS-ER). Diabetes Obes Metab. 2018;20(1):50–9.PubMedCrossRef
23.
go back to reference Ferreira JP, et al. Hospitalization costs due to hypoglycemia in patients with diabetes: a microcosting approach. Diabetes Therapy. 2020;11(10):2237–55.PubMedPubMedCentralCrossRef Ferreira JP, et al. Hospitalization costs due to hypoglycemia in patients with diabetes: a microcosting approach. Diabetes Therapy. 2020;11(10):2237–55.PubMedPubMedCentralCrossRef
24.
go back to reference Laires PA, et al. The cost of managing severe hypoglycemic episodes in type 2 diabetic patients. Expert Rev Pharmacoecon Outcomes Res. 2016;16(2):315–25.PubMedCrossRef Laires PA, et al. The cost of managing severe hypoglycemic episodes in type 2 diabetic patients. Expert Rev Pharmacoecon Outcomes Res. 2016;16(2):315–25.PubMedCrossRef
25.
go back to reference Torre C, et al. Real-world prevalence of mild to moderate hypoglycemic episodes in type 2 diabetes in Portugal: results from the HIPOS-PHARMA study. Prim Care Diabetes. 2018;12(6):537–46.PubMedCrossRef Torre C, et al. Real-world prevalence of mild to moderate hypoglycemic episodes in type 2 diabetes in Portugal: results from the HIPOS-PHARMA study. Prim Care Diabetes. 2018;12(6):537–46.PubMedCrossRef
26.
go back to reference Sepulveda E, et al. Differentiating hypoglycemia awareness status from hypoglycemia experience in tools for measuring impaired awareness of hypoglycemia. Diabetes Technol Ther. 2020;22(7):541–5.PubMedPubMedCentralCrossRef Sepulveda E, et al. Differentiating hypoglycemia awareness status from hypoglycemia experience in tools for measuring impaired awareness of hypoglycemia. Diabetes Technol Ther. 2020;22(7):541–5.PubMedPubMedCentralCrossRef
27.
go back to reference Azevedo S, et al. The impact of prolonged use of continuous subcutaneous insulin infusion in the control of type-1 diabetes. Acta Med Port. 2022;32(1):17–24.CrossRef Azevedo S, et al. The impact of prolonged use of continuous subcutaneous insulin infusion in the control of type-1 diabetes. Acta Med Port. 2022;32(1):17–24.CrossRef
28.
go back to reference Pereira CA, Almeida R, Dores J. Characteristics of hypoglycaemic episodes in diabetic patients treated at the emergency room of a Portuguese tertiary centre, 2012–2016. Endocrinol Diabet Metab. 2020;3(3):e00150.CrossRef Pereira CA, Almeida R, Dores J. Characteristics of hypoglycaemic episodes in diabetic patients treated at the emergency room of a Portuguese tertiary centre, 2012–2016. Endocrinol Diabet Metab. 2020;3(3):e00150.CrossRef
29.
go back to reference Pereira M, Tavares H, Carvalho AJ. O Impacto da Hipoglicemia no Resul-tado Clínico de Doentes Diabéticos Não-críticos Internados em Serviços Médicos: Um Estudo de Caso-controlo. Revista Portuguesa de Diabetes. 2016;11(1):3–9. Pereira M, Tavares H, Carvalho AJ. O Impacto da Hipoglicemia no Resul-tado Clínico de Doentes Diabéticos Não-críticos Internados em Serviços Médicos: Um Estudo de Caso-controlo. Revista Portuguesa de Diabetes. 2016;11(1):3–9.
30.
go back to reference Esteves C, et al. Severe hypoglycaemia in diabetic patients in pre-hospital and emergency department care: a cross-sectional survey. BMC Res Notes. 2018;11(1):249.PubMedPubMedCentralCrossRef Esteves C, et al. Severe hypoglycaemia in diabetic patients in pre-hospital and emergency department care: a cross-sectional survey. BMC Res Notes. 2018;11(1):249.PubMedPubMedCentralCrossRef
31.
go back to reference Marques A, et al. Estudo HiposRainha–Hipoglicémias Severas Numa Viatura Médica de Emergência e Reanimação. Revista Portuguesa de Diabetes. 2019;14(1):3–10. Marques A, et al. Estudo HiposRainha–Hipoglicémias Severas Numa Viatura Médica de Emergência e Reanimação. Revista Portuguesa de Diabetes. 2019;14(1):3–10.
32.
go back to reference Coelho JF, et al. Caracterização das hipoglicémias severas em doentes diabéticos assistidos por uma viatura médica de emergência e reanimação. Revista Portuguesa de Diabetes. 2010;5(3):100–5. Coelho JF, et al. Caracterização das hipoglicémias severas em doentes diabéticos assistidos por uma viatura médica de emergência e reanimação. Revista Portuguesa de Diabetes. 2010;5(3):100–5.
33.
go back to reference Pereira M, et al. Trends in prevalence of diabetes mellitus and mean fasting glucose in Portugal (1987–2009): a systematic review. Public Health. 2014;128(3):214–21.PubMedCrossRef Pereira M, et al. Trends in prevalence of diabetes mellitus and mean fasting glucose in Portugal (1987–2009): a systematic review. Public Health. 2014;128(3):214–21.PubMedCrossRef
34.
go back to reference Little S, et al. Comparison of optimised MDI versus pumps with or without sensors in severe hypoglycaemia (the hypo COMPaSS trial). BMC Endocr Disord. 2012;12(1):33.PubMedPubMedCentralCrossRef Little S, et al. Comparison of optimised MDI versus pumps with or without sensors in severe hypoglycaemia (the hypo COMPaSS trial). BMC Endocr Disord. 2012;12(1):33.PubMedPubMedCentralCrossRef
35.
go back to reference Gold AE, Macleod KM, Frier BM. Frequency of severe hypoglycemia in patients with type I diabetes with impaired awareness of hypoglycemia. Diabetes Care. 1994;17(7):697–703.PubMedCrossRef Gold AE, Macleod KM, Frier BM. Frequency of severe hypoglycemia in patients with type I diabetes with impaired awareness of hypoglycemia. Diabetes Care. 1994;17(7):697–703.PubMedCrossRef
36.
go back to reference Núñez M, et al. Epidemiology, quality of life, and costs associated with hypoglycemia in patients with diabetes in spain: a systematic literature review. Diabetes Therapy. 2019;10(2):375–92.PubMedPubMedCentralCrossRef Núñez M, et al. Epidemiology, quality of life, and costs associated with hypoglycemia in patients with diabetes in spain: a systematic literature review. Diabetes Therapy. 2019;10(2):375–92.PubMedPubMedCentralCrossRef
37.
go back to reference Donnelly LA, et al. Frequency and predictors of hypoglycaemia in type 1 and insulin-treated type 2 diabetes: a population-based study. Diabet Med. 2005;22(6):749–55.PubMedCrossRef Donnelly LA, et al. Frequency and predictors of hypoglycaemia in type 1 and insulin-treated type 2 diabetes: a population-based study. Diabet Med. 2005;22(6):749–55.PubMedCrossRef
38.
go back to reference Elliott L, et al. Hypoglycemia event rates: a comparison between real-world data and randomized controlled trial populations in insulin-treated diabetes. Diabetes Ther. 2016;7(1):45–60.PubMedPubMedCentralCrossRef Elliott L, et al. Hypoglycemia event rates: a comparison between real-world data and randomized controlled trial populations in insulin-treated diabetes. Diabetes Ther. 2016;7(1):45–60.PubMedPubMedCentralCrossRef
39.
go back to reference Khunti K, et al. Rates and predictors of hypoglycaemia in 27 585 people from 24 countries with insulin-treated type 1 and type 2 diabetes: the global HAT study. Diabetes Obes Metab. 2016;18(9):907–15.PubMedPubMedCentralCrossRef Khunti K, et al. Rates and predictors of hypoglycaemia in 27 585 people from 24 countries with insulin-treated type 1 and type 2 diabetes: the global HAT study. Diabetes Obes Metab. 2016;18(9):907–15.PubMedPubMedCentralCrossRef
41.
go back to reference Kloos C, et al. Reduction of severe hypoglycaemia in people with type 2 diabetes after a structured inpatient intervention. 2019. Kloos C, et al. Reduction of severe hypoglycaemia in people with type 2 diabetes after a structured inpatient intervention. 2019.
43.
go back to reference American Diabetes Association (ADA). 6. Glycemic targets: standards of medical care in diabetes-2021. Diabetes Care. 2021;44(Suppl 1):S73-s84.CrossRef American Diabetes Association (ADA). 6. Glycemic targets: standards of medical care in diabetes-2021. Diabetes Care. 2021;44(Suppl 1):S73-s84.CrossRef
44.
go back to reference Jakubczyk M, et al. Cost of severe hypoglycaemia in nine European countries. J Med Econ. 2016;19(10):973–82.PubMedCrossRef Jakubczyk M, et al. Cost of severe hypoglycaemia in nine European countries. J Med Econ. 2016;19(10):973–82.PubMedCrossRef
45.
go back to reference Hammer M, et al. Costs of managing severe hypoglycaemia in three European countries. J Med Econ. 2009;12(4):281–90.PubMedCrossRef Hammer M, et al. Costs of managing severe hypoglycaemia in three European countries. J Med Econ. 2009;12(4):281–90.PubMedCrossRef
46.
go back to reference Aazza S, et al. Antioxidant, anti-inflammatory and anti-hyperglycaemic activities of essential oils from thymbra capitata, thymus albicans, thymus caespititius, thymus carnosus, thymus lotocephalus and thymus mastichina from Portugal. Nat Prod Commun. 2022;11(7):1029–38. Aazza S, et al. Antioxidant, anti-inflammatory and anti-hyperglycaemic activities of essential oils from thymbra capitata, thymus albicans, thymus caespititius, thymus carnosus, thymus lotocephalus and thymus mastichina from Portugal. Nat Prod Commun. 2022;11(7):1029–38.
Metadata
Title
Epidemiological, Social and Economic Burden of Severe Hypoglycaemia in Patients with Diabetes Mellitus in Portugal: A Structured Literature Review
Authors
Ana Rita Soares
Marisa Coelho
Marsha Tracey
Davide Carvalho
José Silva-Nunes
Publication date
21-01-2023
Publisher
Springer Healthcare
Published in
Diabetes Therapy / Issue 2/2023
Print ISSN: 1869-6953
Electronic ISSN: 1869-6961
DOI
https://doi.org/10.1007/s13300-022-01358-1

Other articles of this Issue 2/2023

Diabetes Therapy 2/2023 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Webinar | 06-02-2024 | 20:00 (CET)

Mastering chronic pancreatitis pain: A multidisciplinary approach and practical solutions

Severe pain is the most common symptom of chronic pancreatitis. In this webinar, experts share the latest insights in pain management for chronic pancreatitis patients. Experts from a range of disciplines discuss pertinent cases and provide practical suggestions for use within clinical practice.

Sponsored by: Viatris

Developed by: Springer Healthcare